arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

United Therapeutics Corporation

UTHR Health Care Biotechnology: Pharmaceutical Preparations
$492.42
▲ +1.0% Today
as of Sep 4, 16:55 ET
Last 30 days -6.88% Jul 28 → Sep 04
$483.51 $498.37 $513.23 $528.08 $542.94 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$484.33
High
$494.08
Low
$484.33
Volume
$326,991
Avg Vol
$530,078
Mkt Cap
$22.9B
P/E (TTM)
24.08
Beta
—
52w High
$609.35
52w Low
$388.73
Div Yield
—
Shares Out
$43M

Recent Press Releases & News last 60 days · 25 items

Sep 4 · 15:30 Zacks
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound?
Sep 3 · 15:43 Zacks
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis
Sep 2 · 20:37 MT Newswires
United Therapeutics Insider Sold Shares Worth $4,883,839, According to a Recent SEC Filing
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$389
$609
47% of range
Avg surprise (last 3)
-4.6%
Avg reaction (last 2)
+2.5%
100% positive
Latest IV / EM
36%
EM ±5.6% · $490 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$4.86$5.46$6.06$6.67$7.27 Actual $4.86Actual $5.24Actual $5.38Actual $6.17Actual $5.85Actual $6.39Actual $6.63Est $6.29Actual $6.41Est $6.80Actual $7.16Actual $5.82Est $6.73Actual $7.27 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$0$210M$420M$630M$839M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $7.27 — — — — financials
Wed May 6, 2026Mar/2026 $5.82 $6.73 -13.5% -12.2% +4.3% earnings
Tue Sep 30, 2025Sep 2025 $7.16 — — — — financials
Wed Jul 30, 2025Jun/2025 $6.41 $6.80 -5.7% — — earnings
Wed Apr 30, 2025Mar/2025 $6.63 $6.29 +5.4% — +0.8% earnings
Mon Sep 30, 2024Sep 2024 $6.39 — — — — financials
Sun Jun 30, 2024Jun 2024 $5.85 — — — — financials
Sun Mar 31, 2024Mar 2024 $6.17 — — — — financials
Sat Sep 30, 2023Sep 2023 $5.38 — — — — financials
Fri Jun 30, 2023Jun 2023 $5.24 — — — — financials
Fri Mar 31, 2023Mar 2023 $4.86 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$783M$782M—$800M$799M$794M—$749M
Cost of revenue$100M$133M—$101M$88M$92M—$83M
Gross profit$684M$648M—$699M$711M$702M—$666M
Operating income$331M$326M—$388M$364M$383M—$343M
Net income$333M$275M—$339M$310M$322M—$309M
EPS (diluted)$7.27$5.82—$7.16$6.41$6.63—$6.39

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$1.80B$1.28B$1.56B$1.34B$1.59B$1.90B$1.70B$1.55B
Inventory$194M$178M$183M$176M$169M$165M$158M$147M
Total current assets$3.48B$2.87B$3.70B$3.49B$3.83B$3.94B$3.87B$4.00B
Total assets$7.22B$6.71B$7.88B$7.35B$7.91B$7.74B$7.36B$7.12B
Long-term debt————————
Total liabilities$820M$813M$784M$761M$734M$937M$920M$1.02B
Total equity$6.40B$5.90B$7.10B$6.59B$7.17B$6.81B$6.44B$6.10B

Implied volatility — last 90 days

27%34%42%49%57% Jun 07 — IV 41% · EM ±5.7%Jun 08 — IV 41% · EM ±5.4%Jun 09 — IV 40% · EM ±5.0%Jun 10 — IV 42% · EM ±5.0%Jun 11 — IV 38% · EM ±4.2%Jun 12 — IV 39% · EM ±4.0%Jun 15 — IV 48% · EM ±3.5%Jun 16 — IV 57% · EM ±3.4%Jun 17 — IV 44% · EM ±1.8%Jun 19 — IV 31% · EM ±6.8%Jun 22 — IV 30% · EM ±6.3%Jun 23 — IV 32% · EM ±6.6%Jun 24 — IV 31% · EM ±6.3%Jun 25 — IV 30% · EM ±5.8%Jun 26 — IV 28% · EM ±5.4%Jun 29 — IV 32% · EM ±5.6%Jun 30 — IV 30% · EM ±5.1%Jul 01 — IV 30% · EM ±5.0%Jul 02 — IV 32% · EM ±5.2%Jul 03 — IV 33% · EM ±5.2%Jul 06 — IV 34% · EM ±4.7%Jul 07 — IV 33% · EM ±4.4%Jul 08 — IV 38% · EM ±4.7%Jul 09 — IV 37% · EM ±4.4%Jul 10 — IV 33% · EM ±3.6%Jul 13 — IV 37% · EM ±3.1%Jul 14 — IV 33% · EM ±2.4%Jul 15 — IV 39% · EM ±2.3%Jul 16 — IV 44% · EM ±1.8%Jul 20 — IV 37% · EM ±8.7%Jul 21 — IV 39% · EM ±9.2%Jul 22 — IV 38% · EM ±8.7%Jul 23 — IV 39% · EM ±8.8%Jul 24 — IV 39% · EM ±8.5%Jul 27 — IV 42% · EM ±8.7%Jul 28 — IV 42% · EM ±8.5%Jul 29 — IV 44% · EM ±8.8%Jul 30 — IV 44% · EM ±8.5%Jul 31 — IV 42% · EM ±8.0%Aug 03 — IV 46% · EM ±8.2%Aug 04 — IV 41% · EM ±7.1%Aug 05 — IV 32% · EM ±5.3%Aug 06 — IV 35% · EM ±5.6%Aug 07 — IV 33% · EM ±5.2%Aug 10 — IV 34% · EM ±4.7%Aug 11 — IV 36% · EM ±4.7%Aug 12 — IV 27% · EM ±3.4%Aug 13 — IV 33% · EM ±3.9%Aug 14 — IV 31% · EM ±3.4%Aug 17 — IV 37% · EM ±3.1%Aug 18 — IV 40% · EM ±2.9%Aug 19 — IV 42% · EM ±2.5%Aug 20 — IV 52% · EM ±2.2%Aug 24 — IV 34% · EM ±7.0%Aug 25 — IV 33% · EM ±6.7%Aug 26 — IV 33% · EM ±6.6%Aug 27 — IV 33% · EM ±6.5%Aug 28 — IV 33% · EM ±6.3%Aug 31 — IV 35% · EM ±6.2%Sep 01 — IV 33% · EM ±5.7%Sep 02 — IV 38% · EM ±6.3%Sep 03 — IV 36% · EM ±5.8%Sep 04 — IV 36% · EM ±5.6%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in